Resumo
Definição
Axial spondyloarthritis (axSpA) is a chronic progressive inflammatory arthropathy. Patients present with severe pain and spinal stiffness, which ultimately may lead to radiographic changes in the spine and sacroiliac joints. This radiographic stage is known as ankylosing spondylitis (AS). Progression of disease may lead to spinal fusion. Patients with complete spinal fusion suffer extreme disability.
AS mainly affects the axial skeleton, although peripheral joints, entheses (tendon or ligament attachments to bone), and extra-articular sites such as the eye and bowel are frequently affected.[1][2]
Nonradiographic axial spondyloarthritis (nr-axSpA) describes axial inflammation visible on magnetic resonance imaging (MRI) that has not caused substantial erosive damage to the sacroiliac joints.[Figure caption and citation for the preceding image starts]: Bamboo spineStudent BMJ 2002;10:303-52. © BMJ Publishing Group Ltd 2008 [Citation ends].
História e exame físico
Principais fatores diagnósticos
- HLA-B27 positive
- inflammatory back pain
- iritis/uveitis
- enthesitis
- presentation in late teens and early 20s
- male sex
- positive family history of ankylosing spondylitis (AS)
Outros fatores diagnósticos
- fatigue
- sleep disturbance
- tenderness at sacroiliac joint
- dyspnea
- loss of lumbar lordosis
- peripheral joint involvement
- kyphosis
- psoriasis
- symptoms of inflammatory bowel disease
Fatores de risco
- HLA-B27
- endoplasmic reticulum aminopeptidase 1 (ERAP1) and interleukin-23 receptor (IL23R) gene polymorphisms
- positive family history of ankylosing spondylitis (AS)
- male sex
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- pelvic x-ray
Investigações a serem consideradas
- HLA-B27
- MRI
- cervical spine x-ray (lateral)
- lumbar spine x-ray (lateral)
- thoracic spine x-ray (lateral)
- ultrasound
Algoritmo de tratamento
adults with pain and/or stiffness
adults without pain and/or stiffness
children
adults with pain and/or stiffness refractory to 2 NSAIDs and nonpharmacologic measures
Colaboradores
Autores
Antoni Chan, MBChB, FRCP, PhD
Consultant
Rheumatology Department
Royal Berkshire NHS Foundation Trust
Reading
UK
Declarações
AC has served on the advisory boards for MSD, Novartis, and Sanofi; contributed to educational events for Janssen, MSD, Novartis, Sanofi, and Celgene; been on the speaker bureau for Janssen, Pfizer, and Novartis; and received travel grants from AbbVie, UCB, Lilly, and Pfizer to attend educational conferences.
Sarah Sacks, MBBS, BSc
Specialist Registrar in Rheumatology
Stoke Mandeville Hospital
Aylesbury
UK
Declarações
SS declares that she has no competing interests.
Agradecimentos
Dr Antoni Chan and Dr Sarah Sacks would like to gratefully acknowledge Dr Jessica Gunn, Dr Sarah Keidel, Dr Millicent Stone, Dr Raj Sengupta, Dr Athimalaipet V. Ramanan, and Dr Emma Pomeroy, the previous contributors to this topic. We would like to gratefully acknowledge the late Dr Andrew Keat, Consultant Physician and Rheumatologist at Northwick Park Hospital for his contribution to this topic as a peer reviewer.
Declarações
JG, SK, RS, and AVR declare that they have no competing interests. MS is an author of several references cited in this topic. EP is an author of a reference cited in this topic.
Revisores
Roger Sturrock, MD, FRCP
Professor of Rheumatology
Centre for Rheumatic Diseases
University Department of Medicine
Glasgow Royal Infirmary University Trust
Glasgow
UK
Declarações
RS is an author of a reference cited in this topic.
Karl Gaffney, BCh, BAO (Hons), FRCPI, FRCP
Consultant
Norfolk and Norwich University Hospital
Norwich and the Cromer & District Hospital
Cromer
UK
Declarações
KG is an author of a reference cited in this topic.
Alexios G. Carayannopoulos, DO, MPH
Interventional Spine Physiatrist
Pain Medicine Specialist
Medical Director
Spine Center
Lahey Clinic
Burlington
MA
Declarações
AGC declares that he has no competing interests.
Referências
Principais artigos
Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):19-34.Texto completo Resumo
Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis andnonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019 Oct;71(10):1599-613.Texto completo Resumo
National Institute for Health and Care Excellence (UK). Spondyloarthritis in over 16s: diagnosis and management. Jun 2017 [internet publication].Texto completo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
Diagnósticos diferenciais
- Osteoarthritis
- Diffuse idiopathic skeletal hyperostosis (DISH)
- Psoriatic arthritis
Mais Diagnósticos diferenciaisDiretrizes
- ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
- EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases
Mais DiretrizesFolhetos informativos para os pacientes
Axial spondyloarthritis: what are the treatment options?
Axial spondyloarthritis: what is it?
Mais Folhetos informativos para os pacientesVideos
Aspiration and injection of the knee: animated demonstration
Aspiration and injection of the shoulder animated demonstration
Mais vídeos
Conectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal